Back to search

Switzerland· 68952001

Omvoh 100 mg, solution injectable en stylo prérempli

A mirikizumab product containing mirikizumabum, registered in Switzerland by Eli Lilly (Suisse) SA and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat B (Swissmedic)ATC L04AC24

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedOmvoh 100 mg, solution injectable en …ATCL04AC24REGISTER NO.68952001PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Mirikizumab is registered in 13 of 19 countries.

Countries holding a registration under ATC L04AC24 (mirikizumab), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 8 of them publish a price we can compare per daily dose

Mirikizumab · ATC L04AC24

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of mirikizumab costs, country by country.

Normalised to the WHO defined daily dose (7.1 mg), so markets compare like for like.

  • Switzerland: $30.99 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Mirikizumab · price per daily dose (7.1 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$30.99
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Swissmedic (Switzerland)
Active substance
mirikizumabum
Manufacturer
Eli Lilly (Suisse) SA
Country
Switzerland (CH)
ATC code
L04AC24
ATC class
Mirikizumab
Defined daily dose
7.1 mg, P
Swissmedic category
B
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680689520018
    2 Stk
    CHF 1241.25

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Mirikizumab in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All mirikizumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Omvoh
  • Liechtenstein · Omvoh
  • Norway · Omvoh

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ed112f26-3207-44b1-b531-07c41cfe1adb
GET /v1/drugs/ed112f26-3207-44b1-b531-07c41cfe1adb?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "mirikizumabum 100 mg",
  "valid_from": "2026-02-01",
  "limitations": "[{\"description\":\"<p><strong>Colitis Ulcerosa</strong><br>Die Verschreibung kann nur durch Fach&auml;rzte der Gastroenterologie oder gastroenterologische Universit&auml;tskliniken/Polikliniken erfolgen.<br>Erhaltungstherapie zur Behandlung erwachsener Patienten mit mittelschwerer bis schwerer aktiver Colitis ulcerosa, bei denen konventionelle Therapien oder die Behandlung mit einem Biologikum ungen&uuml;gend angesprochen haben, nicht mehr ansprechen, kontraindiziert sind oder nicht vertragen wurden.&nbsp;<br>Es wird maximal eine Dosis von 200 mg pro Verabreichung alle 4 Wochen verg&uuml;tet.<br>Eine Weiterbehandlung mit OMOVH nach einem Jahr bedarf der Kostengutsprache durch den Krankenversicherer nach vorg&auml;ngiger Konsultation des Vertrauensarztes.<br>Es werden ausschliesslich die Packungen zu 100 mg/ml, 2 Fertigpen zu 1 ml oder 200 mg/2 ml, 1 Fertigpen zu 2 ml f&uuml;r die Erhaltungsphase in der Indikation Colitis Ulcerosa verg&uuml;tet.<br>Der Indikationscode dieser Limitierung ist an den Krankenversicherer zu &uuml;bermitteln.</p>\",\"costApproval\":null,\"indication\":\"21670.01\",\"isNew\":true,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2026-08-01\",\"validTo\":\"2026-09-30\"}]",
  "galenic_form": "Inj Lös 100 mg/ml Fertpen",
  "therapeutic_area": null,
  "sl_inclusion_date": "2024-08-01",
  "self_retention_pct": 10
}

See everything about mirikizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.